# Novo Nordisk A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/novonordisk). ## Overview Novo Nordisk A/S is a Denmark-based healthcare company focused on medicines and delivery systems for diabetes, obesity care, and rare diseases. It develops, manufactures, and markets branded prescription therapies and associated devices across a global commercial footprint from its headquarters in Denmark. ## Products & services • Diabetes medicines, including GLP-1 and insulin therapies • Obesity care medicines • Rare disease treatments • Injection and delivery devices • Pharmaceutical manufacturing and supply chain capacity - **Diabetes care** (55%) — Prescription medicines and related products used to treat diabetes, including GLP-1 and insulin therapies. - **Obesity care** (25%) — Anti-obesity prescription medicines and associated patient access solutions. - **Rare disease** (10%) — Specialty treatments for hemophilia and other rare endocrine disorders. - **Delivery devices and other** (10%) — Injection systems, pens, and other supporting pharmaceutical products and services. - Diabetes medicines, including GLP-1 and insulin therapies - Obesity care medicines - Rare disease treatments - Injection and delivery devices - Pharmaceutical manufacturing and supply chain capacity ## Customers Novo Nordisk sells primarily to healthcare systems, payers, pharmacies, and distributors that place prescription medicines with patients through retail, hospital, and specialty channels. End users are patients with chronic metabolic and rare diseases, while access and reimbursement decisions are heavily influenced by public and private payers. - **Public healthcare systems and tender buyers** (primary) — Buy diabetes and rare disease medicines through national reimbursement, tender, and formulary channels. - **Commercial payers and pharmacy benefit managers** (primary) — Buy or reimburse branded medicines based on access, rebates, and utilization management terms. - **Pharmacies and distributors** (secondary) — Dispense and distribute the company’s prescriptions to patients across retail and specialty channels. - **Hospitals and specialty clinics** (secondary) — Use selected rare disease and injectable therapies in clinical settings. - **Patients** (primary) — Ultimate users of diabetes and obesity medicines, often via reimbursement or self-pay pathways. - Public healthcare systems and national payers - Commercial insurers and pharmacy benefit managers - Retail and specialty pharmacies - Hospitals and treatment centers - Patients with diabetes, obesity, and rare diseases ## Geography Novo Nordisk markets its products in around 170 countries and operates across major regions including the Americas, International Operations, and APAC. The filings highlight that sales performance varies by region, with the United States especially important because of its pricing, rebate, and access dynamics, while Europe, China, and other international markets shape volume growth and product mix. - **Americas** (45%) — Estimated from filings and business mix; United States is the key market. - **International Operations** (40%) — Includes Europe, emerging markets, and other non-Americas markets. - **APAC** (15%) — Asia-Pacific markets, including China, contribute meaningful growth. - Commercial presence in around 170 countries - Large U.S. exposure through branded prescription channels - International Operations spans Europe, emerging markets, and APAC - China is an important obesity and diabetes market - Regional access, pricing, and reimbursement drive mix ## Strategy Novo Nordisk’s strategy centers on expanding access to its core chronic-disease medicines, broadening patient reach, and supporting launches across its major therapeutic areas. The company is also investing in manufacturing and supply chain capacity so it can support higher volumes, protect supply reliability, and maintain access across diverse reimbursement systems. - **Expand patient reach** (medium-term) — Long-term growth depends on getting more patients onto chronic disease therapies through access and reimbursement channels. - **Scale manufacturing capacity** (medium-term) — Higher volumes in diabetes and obesity require more API, fill-finish, and packaging capacity. - **Strengthen obesity franchise** (medium-term) — Obesity care is a major growth engine and needs broad physician, payer, and patient adoption. - **Defend core diabetes leadership** (long-term) — Diabetes remains the base business and supports scale, cash generation, and commercial relationships. - Expand patient access and affordability across payer systems - Scale obesity and diabetes launches across key markets - Increase manufacturing, fill-finish, and API capacity - Broaden global supply chain flexibility - Defend and extend core franchises through life-cycle management ## Risks Novo Nordisk faces pricing, reimbursement, and access pressure in the U.S. and other major markets because its products are sold through heavily managed healthcare systems. The company is also exposed to patent disputes, product competition, supply interruptions, and impairment risk in its pipeline and intangible assets, all of which can affect growth and reported earnings. - **U.S. pricing and rebate pressure** [high] — Sales depend heavily on managed access channels where rebates, 340B, and payer terms affect realized prices. - **Patent and exclusivity disputes** [high] — Core molecules and formulations face legal challenges and potential loss of protection over time. - **Competitive pressure in GLP-1 and insulin** [high] — Therapy classes with strong demand also attract intense competition and market-share shifts. - **Manufacturing and supply disruptions** [high] — Biopharma supply depends on complex API, fill-finish, and packaging networks. - **Intangible asset impairment** [medium] — Pipeline projects can fail or underperform, forcing non-cash write-downs. - U.S. rebate and pricing pressure can reduce realized sales - Patent and exclusivity disputes can limit product protection - Competition in GLP-1 and insulin markets can erode share - Supply chain or manufacturing issues can constrain volumes - Pipeline asset impairments can hit reported earnings ## Accounting The company’s results are affected by rebate provisions, especially in the U.S. 340B program, where reversals can create large non-cash swings in reported sales without changing cash flow. Investors should also watch intangible asset impairment judgments, foreign-currency hedging, and capitalized manufacturing investments, because these can materially affect operating profit, financial items, and reported asset values. - **340B provision reversals** — Reported sales and comparability - **Intangible asset impairment** — Operating profit and asset base - **Foreign currency hedging** — Net financial items and earnings - **Capitalized manufacturing investment** — PPE, depreciation, and cash flow - **Free cash flow definition** — Cash flow presentation - 340B rebate provisions can move reported sales without cash impact - Intangible asset impairment can create large non-cash charges - Foreign exchange hedging affects financial items and earnings - Capital expenditure and supply chain assets affect depreciation - Free cash flow definition changes can affect comparability --- *Last updated: 2026-10-24T15:14:34.615129+00:00*